Silence Therapeutics plc
SLN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.47 | 1.64 | 1.77 | -1.33 |
| FCF Yield | -20.88% | -7.78% | -11.31% | 1.05% |
| EV / EBITDA | -4.16 | -9.10 | -5.82 | -9.91 |
| Quality | ||||
| ROIC | -34.70% | -55.96% | -71.96% | -48.51% |
| Gross Margin | 72.70% | 59.34% | 37.83% | 39.94% |
| Cash Conversion Ratio | 1.87 | 0.78 | 1.13 | -0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 25.94% | 26.91% | 58.11% | 270.55% |
| Free Cash Flow Growth | -72.23% | 14.16% | -938.74% | 148.47% |
| Safety | ||||
| Net Debt / EBITDA | 2.47 | 1.08 | 0.90 | 1.62 |
| Interest Coverage | 0.00 | -1,458.94 | -1,298.72 | -5,726.75 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 112.78 | -89.72 | 205.93 | 50.52 |